Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? No

BMJ

Volumn 343, Issue , 2011, Pages d6397-

  Steele, Robert J C ^a   Brewster, David H ^b  

^a Scottish Bowel Screening Programme   (United Kingdom)

^b Scottish Cancer Registry   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLORECTAL TUMOR; HEALTH CARE QUALITY; HUMAN; MASS SCREENING; METHODOLOGY; MORTALITY; NOTE;

COLORECTAL NEOPLASMS; HUMANS; MASS SCREENING; PROGRAM EVALUATION;

EID: 84856401507     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.d6397     Document Type: Article

References (15)

1. Raffle A, Gray M. Screening: evidence and practice. Oxford University Press, 2007.
2. Shapiro S, Venet W, Strax P, Venet L. Periodic screening for breast cancer: the health insurance plan project and its sequelae, 1963-1986. Johns Hopkins University Press, 1988.
3. Tabar L, Fagerberg G, Duffy SW, Day NE. The Swedish two-county trial of mammographic screening for breast cancer recent results and calculation of benefit. J Epidemiol Community Health 1989; 43: 107-14.
4. Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linnell F, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988; 297: 943-8.
5. Bjurstam N, Bjorneld L, Duffy SW, Smith TC, Cahlin E, Eriksson O, et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomisation. Cancer 1997; 80: 2091-9.
6. Roberts MM, Alexander FE, Anderson TJ, Chetty U, Donnan PT, Forrest P, et al. Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet 1990; 335: 241-6.
7. Miller AB, To T, Baines CJ, Wall C. Canadian national breast screening study-2: 13-year results of a randomised trial in women aged 50-59 years. J Natl Cancer Inst 2000; 92: 1490-9.
8. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesotal colon cancer control study. N Engl J Med 1993; 328: 1365-71.
9. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-7.
10. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-71.
11. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomised clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 2008; 95: 1029-36.
12. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomised trials of cancer screening. J Natl Cancer Inst 2002; 94: 167-73.
13. Black WC, Haggstrom DA, Welch HG. Response re: all-cause mortality in randomized controlled trials of cancer screening. J Natl Cancer Inst 2002; 94: 866.
14. Health Scotland. Bowel screening: know the facts. 2011. www.healthscotland.com/documents/2064.aspx
15. NHS Scotland. Scottish bowel screening programme: key performance indicators. 2010. www.isdscotland.org/Health-Topics/Cancer/Bowel-Screening/KPI_Report.pdf.